Overview

Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease

Status:
Terminated
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the long term safety and tolerability of sumanirole as measured by safety labs, ECG monitoring, vital signs, and adverse event reports in subjects with Parkinson's Disease who participated in previous sumanirole studies.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer